Abstract | PURPOSE: PATIENTS AND METHODS: RESULTS: Symptomatic response during the first four weeks was seen after pamidronate, but not with placebo (P < 0.05). Quality of life was maintained with pamidronate and deteriorated after placebo (P < 0.05). Resorption markers did not decrease after placebo, but NTx and Crosslaps both decreased by 70% after pamidronate (P = 0.001). A second infusion of pamidronate did not decrease resorption further, but maintained the suppression of resorption at similar levels for a further four weeks. Symptomatic response to pamidronate correlated closely with the rate of bone resorption; it was more frequent in those patients with an initial NTx value of < 2 times the upper limit of normal (17 of 27, 62%) and in those where the level of Ntx returned to normal (19 of 32, 59%), than in the patients with either high baseline values of NTx (> 2 times the upper limit of normal) or Ntx levels which failed to normalise for whom the response frequencies were 2 of 16 (13%) and 0 of 11 (0%), respectively. CONCLUSIONS:
|
Authors | J J Vinholes, O P Purohit, M E Abbey, R Eastell, R E Coleman |
Journal | Annals of oncology : official journal of the European Society for Medical Oncology
(Ann Oncol)
Vol. 8
Issue 12
Pg. 1243-50
(Dec 1997)
ISSN: 0923-7534 [Print] England |
PMID | 9496390
(Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Diphosphonates
- Pamidronate
|
Topics |
- Adult
- Aged
- Bone Neoplasms
(drug therapy, metabolism, secondary)
- Bone Resorption
(metabolism)
- Diphosphonates
(pharmacokinetics, therapeutic use)
- Double-Blind Method
- Female
- Humans
- Male
- Middle Aged
- Pain Measurement
- Pamidronate
- Quality of Life
- Treatment Outcome
|